Autonomix Medical (AMIX) said Monday three patients responded to radio frequency pain management with femoral access in an ongoing clinical trial evaluating its potential to manage pain in pancreatic cancer patients without the use of opioids.
Two patients in the same group, but treated with brachial access, didn't show improvement in their pain scores, or worsened, the company said, but all paitents treated with the technology were able to eliminate their opioid use at four to six weeks post-procedure.
The company said the preliminary results came from the first five "lead-in" patients in its ongoing proof-of-concept human trial assessing the delivery of transvascular energy to ablate problematic nerves and mitigate pain in pancreatic cancer pain patients.
The trial is expected to finish enrolment by yearend, the company said.
The company's technology platform uses a catheter-based microchip sensing array antenae that can detect neural signals. Once target nerves are identified, the treatment uses radio frequency ablation technology to kill targeted nerves, the company said.
Autonomix shares soared more than 150% in recent Monday premarket activity.
Price: 19.59, Change: +11.88, Percent Change: +154.10
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。